ActoGeniX: 20 million euros round


Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.



Leiden - Dutch biopharmaceutical company Crucell is teaming up with the International AIDS Vaccine Initiative (IAVI) to test a combination of two AIDS vaccines. Clinical Phase I trials in the United States and Africa represent a...



Mechelen - Galapagos certainly has faith in its own products. The Belgian biotech company has reacquired the full rights to GLPG0634, a small molecule drug against rheumatoid arthritis, from GlaxoSmithKline (GSK). GLPG0634, once...



Brussels – European Biotech lobby group EuropaBio has welcomed the inauguration of the EU’s new High-Level Group on Key Enabling Technologies (KET) that will be advising the European Commission. Industrial biotechnology has been...



Liège – Japanese chemistry company Kaneka is acquiring Eurogentec SA, a Belgian contract manufacturer and reagents supplier, in a strategic move to build up its presence in the biopharmaceutical and diagnostics sectors. The...



Delft – DSM BioSolutions has entered into an agreement with the UK’s Novacta Biosystems to manufacture Novacta’s peptide antibiotic candidate for pre-clinical and Phase I clinical trials. The substance is a possible treatment for...



Brussels – The European Commission has tabled the translation arrangements that were lacking to bring about the long-awaited single EU patent. If adopted, the measures – which foresee limiting translation of European patent...



Rome/Maastricht – Researchers from the University of Maastricht have presented results from an ongoing clinical trial suggesting a simple, prenatal blood test could be used to detect accurately chromosomal abnormalities in the...



Brussels – The European Biotechnology Network ( kicked-off its new “Biotechnology Funding Hub” service in April. “We will bring all relevant information on funding opportunities and new funding...



ThromboGenics NV‘s (Leuven) recombinantly expressed protease microplasmin for pharmacological vitreolysis has met the primary endpoint in a Phase III trial including 326 patients in the US. Comparison of a single injection of...

Displaying results 81 to 90 out of 304

< Previous 81-90 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues